Volume 129, Issue 3

Cover Figure: CCL2 is involved in pathobiology of systemic mastocytosis.  See the article by Greiner et al.

WASHINGTON, January 19, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry
In a study of a uniquely large series of systemic and localized immunoglobulin light chain (AL) amyloidosis, Kourelis and coworkers report on immunoglobulin light-chain (IGVL) gene usage, relating it to key aspects of the pathogenesis and important clinical features of the disease.

B-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphoma
This paper identifies a novel, MALT1-dependent, MYC-mediated regulatory circuit that is active in a subgroup of mantle cell lymphomas (MCLs) and is required for the survival of MCL cells. These experimental data have therapeutic implications given the availability of tools that can pharmacologically target this axis (eg, MALT1 inhibitors).

How I treat cryoglobulinemia
This timely, succinctly written How I Treat article covers the classification, diagnostic workup, therapeutic options, and outcome of cryoglobulinemias. It presents instructive clinical vignettes, figures, and tables that will particularly serve consulting hematologists dealing with these complex disorders.

Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus
Cusan et al identify a proline-rich regulatory domain in the transcription factor HOXB4, the presence of which negatively correlates with the leukemic potential of Hox genes.

p53−/− synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia
Zhang et al show the cooperation between p53 deletion and NRASG12D in the development of acute myeloid leukemia, and they shed light on the megakaryocyte-erythroid progenitor as the leukemia-initiating cell targeted by p53 deletion and NRASG12D cooperation in mice.

Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study
This large retrospective analysis of over 180 patients with primary ocular adnexal MALT lymphoma presents treatments and follow-up results spanning a period of more than 30 years. The study reaffirms the excellent long-term control of orbital MALT lymphoma with localized radiotherapy.

Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
This review of MYC and BCL2 deregulation in aggressive B-cell lymphomas is important for clinical practice in the lymphoma world. It highlights a wealth of data that are useful for the workup of and treatment strategies for double-hit lymphoma.

Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
Rosenblatt and Avigan present an up-to-date Blood Spotlight about the current understanding of PD-1/PD-L1 and the therapeutic potential of checkpoint inhibitors in multiple myeloma.

This week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.